Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4K | $81.0K | $111K | $130K | $77.0K | $46.0K | $120K | $146K | $401K | $360K |
| Revenue growth | — | 122.8% | 37.0% | 17.1% | -40.8% | -40.3% | 160.4% | 21.7% | 175.0% | -10.3% |
| Gross profit | $36.3K | $81.0K | — | — | — | — | — | $146K | $373K | $336K |
| Gross margin | 99.7% | 100.0% | — | — | — | — | — | 100.0% | 93.0% | 93.4% |
| Operating income | -$7.79M | -$8.37M | -$7.65M | -$8.43M | -$2.75M | -$26.3M | -$19.0M | -$15.2M | -$11.6M | -$15.6M |
| Operating margin | -21414.0% | -10338.6% | -6889.8% | -6486.2% | -3574.1% | -57191.0% | -15838.1% | -10439.5% | -2881.6% | -4350.1% |
| Net income | -$8.64M | -$9.44M | -$12.5M | -$14.6M | -$11.3M | -$44.3M | -$18.5M | -$10.4M | -$8.98M | -$14.2M |
| Net margin | -23755.4% | -11660.1% | -11277.3% | -11267.6% | -14639.9% | -96311.5% | -15438.0% | -7145.2% | -2239.2% | -3959.4% |
| EPS (diluted) | -$2.10 | -$1.74 | -$1.64 | -$0.66 | -$28.56 | -$37.30 | -$5.11 | -$2.47 | -$1.16 | -$1.58 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.00M | -$3.85M | -$5.10M | -$6.92M | -$1.96M | -$3.33M | -$5.91M | -$6.43M | -$8.23M | -$10.8M |
| Capital expenditures | $189K | $3.62K | $12.9K | $35.6K | — | $30.7K | $265K | $171K | $106K | $116K |
| Free cash flow | -$5.19M | -$3.86M | -$5.12M | -$6.95M | — | -$3.36M | -$6.18M | -$6.60M | -$8.34M | -$10.9M |
| Share buybacks | — | — | — | — | — | — | — | — | — | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | $21.0M | $1.71M | $884K | $548K | $1.51M |
| Total assets | $1.58M | $1.76M | $1.19M | $1.47M | $4.35M | $22.5M | $16.4M | $12.6M | $12.3M | $4.08M |
| Total liabilities | $6.58M | $8.60M | $9.83M | $14.2M | $5.68M | $856K | $603K | $2.61M | $3.75M | — |
| Long-term debt | — | — | — | — | — | $250K | — | — | — | — |
| Shareholders' equity | -$5.00M | -$6.84M | -$8.64M | -$12.8M | -$1.33M | $21.6M | $10.3M | $10.0M | $8.53M | $357K |
| Retained earnings | -$42.0M | -$51.4M | -$63.9M | -$78.6M | -$89.8M | -$134M | -$153M | -$147M | -$156M | -$170M |
| Shares (wtd avg diluted) | 4.70M | 6.11M | 11.7M | 77.9M | 716K | 1.19M | 3.62M | 4.22M | 7.76M | 8.99M |
Every figure is extracted from BioRestorative Therapies, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.